About us

Nucleosyn is a company created in 2006 developing compounds derived from Organic Chemistry dedicated to genomics, (bio)-analysis, vaccines, and diagnostic.

Nucleosyn is the French innovation and R&D subsidiary of the Biosolve Group. Its main objective, since its creation in 2006, has been to develop new ranges of innovative products to implement the catalog of reagents and solvents already offered by the group. These specialty products are widely addressed to the private sector (chemical, pharmaceutical, cosmetics, biotechnology industry, biomedical analysis laboratory) and to the public domain (hospitals, academic research institution, CNRS, INSERM, etc.).

Nucleosyn has developed a significant range of monomers used in DNA and RNA chemistry (e.g. Phosphoramidites and modifiers). This range of products was followed by a set of Synthetic Lipids molecules (used in vaccines as vectorization/transfection agents) with many customized compounds. To date, Nucleosyn is developing a new set of molecules labeled with stable isotopes (²H, ¹³C, ¹⁵N) making it possible to "trace" and quantify biomarkers, drug candidates, metabolites by mass spectrometry (MS) or nuclear magnetic resonance (NMR).

One of the common points of all these molecules is their use in the clinical diagnostic and in the biomedical analysis industry as molecular reagents and/or tools.